Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases.
Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases.
复制标题
间充质干细胞衍生的外泌体作为肝病的新治疗策略。
DOI：
10.1038/emm.2017.63
复制
发表时间：
2017-06-16
影响因子：
12.8
通讯作者：
Liu Y
中科院分区：
文献类型：
--
作者：
Lou G;Chen Z;Zheng M;Liu Y
间充质干细胞（MSC）作为肝病治疗的管理具有很大的希望。骨髓间充质干细胞可以分化为肝细胞，减轻肝脏炎症，促进肝脏再生，并分泌保护性细胞因子。然而，MSC移植中医源性肿瘤形成、细胞排斥反应和输注毒性的风险仍未得到解决。越来越多的证据表明，一种新的无细胞疗法，MSC分泌的外泌体，可能构成一种令人信服的替代方案，因为它们比相应的MSC具有优势。它们比它们的亲本细胞更小，更不复杂，因此更容易生产和储存，它们缺乏活细胞，并且它们没有肿瘤形成的风险。此外，它们的免疫原性低于其亲本细胞，因为它们的膜结合蛋白含量较低。本文综述了MSC外泌体的生物起源及其生理功能，并强调了MSC来源的外泌体在恢复组织稳态方面的特定生化潜力。此外，我们总结了近年来在MSC治疗各种肝脏疾病，包括肝纤维化，急性肝损伤和肝细胞癌的作用外泌体的进展。本文还讨论了未来使用基于外泌体的治疗肝病的潜在挑战和策略。
The administration of mesenchymal stem cells (MSCs) as a therapy for liver disease holds great promise. MSCs can differentiate into hepatocytes, reduce liver inflammation, promote hepatic regeneration and secrete protective cytokines. However, the risks of iatrogenic tumor formation, cellular rejection and infusional toxicity in MSC transplantation remain unresolved. Accumulating evidence now suggests that a novel cell-free therapy, MSC-secreted exosomes, might constitute a compelling alternative because of their advantages over the corresponding MSCs. They are smaller and less complex than their parent cells and, thus, easier to produce and store, they are devoid of viable cells, and they present no risk of tumor formation. Moreover, they are less immunogenic than their parent cells because of their lower content in membrane-bound proteins. This paper reviews the biogenesis of MSC exosomes and their physiological functions, and highlights the specific biochemical potential of MSC-derived exosomes in restoring tissue homeostasis. In addition, we summarize the recent advances in the role of exosomes in MSC therapy for various liver diseases, including liver fibrosis, acute liver injury and hepatocellular carcinoma. This paper also discusses the potential challenges and strategies in the use of exosome-based therapies for liver disease in the future.
登录
查看更多内容
DOI：
10.1016/j.apsb.2016.02.001
发表时间：
2016-07
期刊：
Acta pharmaceutica Sinica. B
影响因子：
--
作者：
Ha D;Yang N;Nadithe V
通讯作者：
Nadithe V
外泌体作为帕金森氏病疗法的药物。
DOI：
10.1016/j.jconrel.2015.03.033
发表时间：
2015-06-10
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Haney MJ;Klyachko NL;Zhao Y;Gupta R;Plotnikova EG;He Z;Patel T;Piroyan A;Sokolsky M;Kabanov AV;Batrakova EV
通讯作者：
Batrakova EV
DOI：
10.1073/pnas.0308413101
发表时间：
2004-06-29
影响因子：
11.1
作者：
Fevrier, B;Vilette, D;Raposo, G
通讯作者：
Raposo, G
影响因子：
24.5
作者：
De Boeck, Astrid;Pauwels, Patrick;De Wever, Olivier
通讯作者：
De Wever, Olivier
影响因子：
20.3
作者：
de Gassart, A;Géminard, C;Vidal, M
通讯作者：
Vidal, M